baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Argen X NV/ NL0010832176 /

2024-03-21 2:54:16 PM	Chg. -	Volume	Bid-	Ask-	Market Capitalization	Dividend Y.	P/E Ratio
383.7400USD	-	100 Turnover: 38,374	-Bid Size: -	-Ask Size: -	21.27 bill.USD	-	-

GlobeNewswire 04-16 argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Pa...

GlobeNewswire 03-27 argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

GlobeNewswire 03-26 argenx Announces Annual General Meeting of Shareholders on May 7, 2024

GlobeNewswire 03-26 argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thr...

GlobeNewswire 03-07 argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of ...

GlobeNewswire 02-29 argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

GlobeNewswire 02-26 argenx to Present at Upcoming Investor Conferences

GlobeNewswire 02-22 argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29,...

GlobeNewswire 02-20 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review f...

GlobeNewswire 01-18 argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcu...

GlobeNewswire 01-08 argenx Highlights 2024 Strategic Priorities

GlobeNewswire 01-02 argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 2023-11-28 argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocyt...

GlobeNewswire 2023-11-16 argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Gene...

GlobeNewswire 2023-11-01 argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scie...

GlobeNewswire 2023-11-01 argenx to Present at Upcoming Investor Conferences

GlobeNewswire 2023-10-31 argenx Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire 2023-10-24 argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023

GlobeNewswire 2023-09-21 argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized M...

GlobeNewswire 2023-09-15 argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Grav...

GlobeNewswire 2023-08-30 argenx to Present at Upcoming Investor Conferences

GlobeNewswire 2022-03-28 argenx announces closing of global offering

GlobeNewswire 2022-03-24 argenx raises $700 million in gross proceeds in a global offering

GlobeNewswire 2022-03-22 argenx announces launch of proposed global offering

GlobeNewswire 2022-03-03 argenx Reports Full Year 2021 Financial Results and Provides Fourth Quarter Business Update

Argen X NV/ NL0010832176 /

If you wish to receive reply to your feedback, please provide your email address.